I'm not sure. Bryostatin was only given during the first 12 weeks and had the 13 week data point. I do not know if they had an issue getting all the patients to come back in for a follow up a month later or not or if they were just presenting the data from when patients were actually taking bryostatin. It's something I would like to see addressed. I would love to see those numbers but in all honesty they may not have been all that impressive since patients would not have been on the drug for 5 weeks. At the same time if the 17 week data wasn't good, in some ways it would be showing that bryostatin was really working earlier I guess. I simply don't know.
News 
Market Data 
Discover 
